Skip to main content
Top
Published in: Clinical and Translational Oncology 3/2017

01-03-2017 | Research Article

Identification of clinical biomarkers for patients with advanced hepatocellular carcinoma receiving sorafenib

Authors: A. Lamarca, O. Abdel-Rahman, I. Salu, M. G. McNamara, J. W. Valle, R. A. Hubner

Published in: Clinical and Translational Oncology | Issue 3/2017

Login to get access

Abstract

Background

Identification of patients with advanced HCC-deriving preferential benefit from sorafenib is desirable, and treatment-related adverse events are potential clinical biomarkers.

Methods

Survival and toxicity data for patients with HCC treated with sorafenib at the Christie NHS Foundation Trust from 11/09 to 02/15 were collected retrospectively.

Results

Eighty-five eligible patients were identified. The most common grade 3 or 4 treatment-related toxicities were hypertension (HTN, 45 %), fatigue (8 %), and hand-foot syndrome (HFS, 8 %). Any-grade HFS and/or worsening HTN (HFS/HTN) were experienced by 58 % of patients. Estimated median progression-free and overall survival (OS) were 4.6 (95 % CI 2.8–5.2) and 6.5 (95 % CI 4.9–8.01) months, respectively. Child–Pugh score (p value <0.001) and the development of HFS/HTN were independent prognostic factors impacting on OS on multivariable analysis. Patients who developed HFS/HTN had median OS of 8.2 months (95 % CI 6.5–12.4) compared with 4.1 (95 % CI 2.7–5.4) for those without this toxicity (Hazard Ratio (HR) 0.4, 95 % CI 0.2–0.7, p value 0.003). The prognostic impact of HFS/HTN was confirmed by landmark analyses limited to patients who lived a minimum of 2 months (p value 0.019) or who developed HFS/HTN in the first 3 months of treatment (p value 0.006).

Conclusion(s)

The development of toxicities specific to sorafenib is associated with prolonged survival in a UK-based HCC patient series; prospective assessment of their significance is required.
Literature
1.
3.
go back to reference Murray CJ, Richards M, Newton J, Fenton K, Anderson H, Atkinson C, et al. UK health performance: findings of the Global Burden of Disease Study 2010. Lancet. 2013;381:997–1020.CrossRefPubMed Murray CJ, Richards M, Newton J, Fenton K, Anderson H, Atkinson C, et al. UK health performance: findings of the Global Burden of Disease Study 2010. Lancet. 2013;381:997–1020.CrossRefPubMed
4.
go back to reference EASL. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908–43.CrossRef EASL. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908–43.CrossRef
5.
go back to reference Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–90.CrossRefPubMed Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–90.CrossRefPubMed
6.
go back to reference Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25–34.CrossRefPubMed Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25–34.CrossRefPubMed
7.
go back to reference Cheng AL, Kang YK, Lin DY, Park JW, Kudo M, Qin S, et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol. 2013;31:4067–75.CrossRefPubMed Cheng AL, Kang YK, Lin DY, Park JW, Kudo M, Qin S, et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol. 2013;31:4067–75.CrossRefPubMed
8.
go back to reference Johnson PJ, Qin S, Park J-W, Park J, Poon R, Raoul J-L, et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol. 2013;31:3517–24.CrossRefPubMed Johnson PJ, Qin S, Park J-W, Park J, Poon R, Raoul J-L, et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol. 2013;31:3517–24.CrossRefPubMed
9.
go back to reference Zhu AX, Rosmorduc O, Evans TR, Ross PJ, Santoro A, Carrilho FJ, et al. SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2015;33:559–66.CrossRefPubMed Zhu AX, Rosmorduc O, Evans TR, Ross PJ, Santoro A, Carrilho FJ, et al. SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2015;33:559–66.CrossRefPubMed
10.
go back to reference Dienstmann R, Brana I, Rodon J, Tabernero J. Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs. Oncologist. 2011;16:1729–40.CrossRefPubMedPubMedCentral Dienstmann R, Brana I, Rodon J, Tabernero J. Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs. Oncologist. 2011;16:1729–40.CrossRefPubMedPubMedCentral
11.
go back to reference Di FF, Rigal O, Menager C, Michel P, Pfister C. Severe clinical toxicities are correlated with survival in patients with advanced renal cell carcinoma treated with sunitinib and sorafenib. Br J Cancer. 2011;105:1811–3.CrossRef Di FF, Rigal O, Menager C, Michel P, Pfister C. Severe clinical toxicities are correlated with survival in patients with advanced renal cell carcinoma treated with sunitinib and sorafenib. Br J Cancer. 2011;105:1811–3.CrossRef
12.
go back to reference Nakano K, Komatsu K, Kubo T, Natsui S, Nukui A, Kurokawa S, et al. Hand-foot skin reaction is associated with the clinical outcome in patients with metastatic renal cell carcinoma treated with sorafenib. Jpn J Clin Oncol. 2013;43:1023–9.CrossRefPubMed Nakano K, Komatsu K, Kubo T, Natsui S, Nukui A, Kurokawa S, et al. Hand-foot skin reaction is associated with the clinical outcome in patients with metastatic renal cell carcinoma treated with sorafenib. Jpn J Clin Oncol. 2013;43:1023–9.CrossRefPubMed
13.
go back to reference Lee WJ, Lee J, Chang S, Lee M, Kang Y, Choi J, et al. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. Br J Dermatol. 2009;161:1045–51.CrossRefPubMed Lee WJ, Lee J, Chang S, Lee M, Kang Y, Choi J, et al. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. Br J Dermatol. 2009;161:1045–51.CrossRefPubMed
14.
go back to reference Reig M, Torres F, Rodriguez-Lope C, Forner A, LLarch N, Rimola J, et al. Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib. J Hepatol. 2014;61:318–24.CrossRefPubMed Reig M, Torres F, Rodriguez-Lope C, Forner A, LLarch N, Rimola J, et al. Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib. J Hepatol. 2014;61:318–24.CrossRefPubMed
15.
go back to reference Di Costanzo GG, de Stefano G, Tortora R, Farella N, Addario L, et al. Sorafenib off-target effects predict outcomes in patients treated for hepatocellular carcinoma. Future Oncol. 2015;11:943–51.CrossRefPubMed Di Costanzo GG, de Stefano G, Tortora R, Farella N, Addario L, et al. Sorafenib off-target effects predict outcomes in patients treated for hepatocellular carcinoma. Future Oncol. 2015;11:943–51.CrossRefPubMed
16.
go back to reference Lamarca A, Feliu J, Barriuso J. Severe toxicity caused by sorafenib in hepatocellular carcinoma match the data from renal cell carcinoma. Br J Cancer. 2012;106:1246.CrossRefPubMedPubMedCentral Lamarca A, Feliu J, Barriuso J. Severe toxicity caused by sorafenib in hepatocellular carcinoma match the data from renal cell carcinoma. Br J Cancer. 2012;106:1246.CrossRefPubMedPubMedCentral
17.
go back to reference Song T, Zhang W, Wu Q, Kong D, Ma W. A single center experience of sorafenib in advanced hepatocellular carcinoma patients: evaluation of prognostic factors. Eur J Gastroenterol Hepatol. 2011;23:1233–8.CrossRefPubMed Song T, Zhang W, Wu Q, Kong D, Ma W. A single center experience of sorafenib in advanced hepatocellular carcinoma patients: evaluation of prognostic factors. Eur J Gastroenterol Hepatol. 2011;23:1233–8.CrossRefPubMed
18.
go back to reference Cho JY, Paik YH, Lim HY, Kim YG, Lim HK, Min YW, et al. Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma. Liver Int. 2013;33:950–7.CrossRefPubMed Cho JY, Paik YH, Lim HY, Kim YG, Lim HK, Min YW, et al. Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma. Liver Int. 2013;33:950–7.CrossRefPubMed
19.
go back to reference Bruix J, Raoul JL, Sherman M, Mazzaferro V, Bolondi L, Craxi A, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol. 2012;57:821–9.CrossRefPubMed Bruix J, Raoul JL, Sherman M, Mazzaferro V, Bolondi L, Craxi A, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol. 2012;57:821–9.CrossRefPubMed
20.
go back to reference Bahig H, Taussky D, Delouya G, Nadiri A, Gagnon-Jacques A, Bodson-Clermont P, et al. Neutrophil count is associated with survival in localized prostate cancer. BMC Cancer. 2015;15:594–1599.CrossRefPubMedPubMedCentral Bahig H, Taussky D, Delouya G, Nadiri A, Gagnon-Jacques A, Bodson-Clermont P, et al. Neutrophil count is associated with survival in localized prostate cancer. BMC Cancer. 2015;15:594–1599.CrossRefPubMedPubMedCentral
21.
go back to reference Wu G, Yao Y, Bai C, Zeng J, Shi D, Gu X, et al. Combination of platelet to lymphocyte ratio and neutrophil to lymphocyte ratio is a useful prognostic factor in advanced non-small cell lung cancer patients. Thorac Cancer. 2015;6:275–87.CrossRefPubMedPubMedCentral Wu G, Yao Y, Bai C, Zeng J, Shi D, Gu X, et al. Combination of platelet to lymphocyte ratio and neutrophil to lymphocyte ratio is a useful prognostic factor in advanced non-small cell lung cancer patients. Thorac Cancer. 2015;6:275–87.CrossRefPubMedPubMedCentral
22.
go back to reference Krenn-Pilko S, Langsenlehner U, Stojakovic T, Pichler M, Gerger A, Kapp KS, et al. The elevated preoperative derived neutrophil-to-lymphocyte ratio predicts poor clinical outcome in breast cancer patients. Tumour Biol. 2016;37(1):361–8.CrossRefPubMed Krenn-Pilko S, Langsenlehner U, Stojakovic T, Pichler M, Gerger A, Kapp KS, et al. The elevated preoperative derived neutrophil-to-lymphocyte ratio predicts poor clinical outcome in breast cancer patients. Tumour Biol. 2016;37(1):361–8.CrossRefPubMed
23.
go back to reference McNamara MG, Templeton AJ, Maganti M, Walter T, Horgan AM, McKeever L, et al. Neutrophil/lymphocyte ratio as a prognostic factor in biliary tract cancer. Eur J Cancer. 2014;50:1581–9.CrossRefPubMed McNamara MG, Templeton AJ, Maganti M, Walter T, Horgan AM, McKeever L, et al. Neutrophil/lymphocyte ratio as a prognostic factor in biliary tract cancer. Eur J Cancer. 2014;50:1581–9.CrossRefPubMed
24.
go back to reference Templeton AJ, McNamara MG, Seruga B, Vera-Badillo FE, Aneja P, Ocana A, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014;106:dju124.CrossRefPubMed Templeton AJ, McNamara MG, Seruga B, Vera-Badillo FE, Aneja P, Ocana A, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014;106:dju124.CrossRefPubMed
25.
go back to reference da Fonseca LG, Barroso-Sousa R, Bento A, Blanco BP, Valente G, Pfiffer T, et al. Pre-treatment neutrophil-to-lymphocyte ratio affects survival in patients with advanced hepatocellular carcinoma treated with sorafenib. Med Oncol. 2014;31:264–0264.CrossRefPubMed da Fonseca LG, Barroso-Sousa R, Bento A, Blanco BP, Valente G, Pfiffer T, et al. Pre-treatment neutrophil-to-lymphocyte ratio affects survival in patients with advanced hepatocellular carcinoma treated with sorafenib. Med Oncol. 2014;31:264–0264.CrossRefPubMed
26.
go back to reference Wei K, Wang M, Zhang W, Mu H, Song T-Q, Song TQ. Neutrophil-lymphocyte ratio as a predictor of outcomes for patients with hepatocellular carcinoma undergoing TAE combined with Sorafenib. Med Oncol. 2014;31:969–0969.CrossRefPubMed Wei K, Wang M, Zhang W, Mu H, Song T-Q, Song TQ. Neutrophil-lymphocyte ratio as a predictor of outcomes for patients with hepatocellular carcinoma undergoing TAE combined with Sorafenib. Med Oncol. 2014;31:969–0969.CrossRefPubMed
27.
go back to reference Zheng YB, Zhao W, Liu BF, Lu L-G, He X, Huang J-W, et al. The blood neutrophil-to-lymphocyte ratio predicts survival in patients with advanced hepatocellular carcinoma receiving sorafenib. Asian Pac J Cancer Prev. 2013;14:5527–31.CrossRefPubMed Zheng YB, Zhao W, Liu BF, Lu L-G, He X, Huang J-W, et al. The blood neutrophil-to-lymphocyte ratio predicts survival in patients with advanced hepatocellular carcinoma receiving sorafenib. Asian Pac J Cancer Prev. 2013;14:5527–31.CrossRefPubMed
28.
go back to reference Pinato DJ, Stebbing J, Ishizuka M, Khan SA, Wasan HS, North BV, et al. A novel inflammatory-based prognostic score in hepatocellular carcinoma: the inflammation based index (IBI). J Hepatol. 2012;57(5):1013–20.CrossRefPubMed Pinato DJ, Stebbing J, Ishizuka M, Khan SA, Wasan HS, North BV, et al. A novel inflammatory-based prognostic score in hepatocellular carcinoma: the inflammation based index (IBI). J Hepatol. 2012;57(5):1013–20.CrossRefPubMed
29.
go back to reference Oken M, Creech R, Tormey D, Horton J, Davis T, McFadden E, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649–55.CrossRefPubMed Oken M, Creech R, Tormey D, Horton J, Davis T, McFadden E, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649–55.CrossRefPubMed
30.
go back to reference Llovet JM, Bru CFAU, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19:329–38.CrossRefPubMed Llovet JM, Bru CFAU, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19:329–38.CrossRefPubMed
32.
go back to reference Eisenhauer EA, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.CrossRefPubMed Eisenhauer EA, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.CrossRefPubMed
33.
go back to reference Bellera CA, Penel N, Ouali M, Bonvalot S, Casali PG, Nielsen OS, et al. Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)dagger. Ann Oncol. 2015;26:865–72.CrossRefPubMed Bellera CA, Penel N, Ouali M, Bonvalot S, Casali PG, Nielsen OS, et al. Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)dagger. Ann Oncol. 2015;26:865–72.CrossRefPubMed
34.
go back to reference Van Houwelingen HC. Dynamic prediction by landmarking in event history analysis. Scand. J. Stat. 2007;34(1):70–85.CrossRef Van Houwelingen HC. Dynamic prediction by landmarking in event history analysis. Scand. J. Stat. 2007;34(1):70–85.CrossRef
36.
go back to reference Ogasawara S, Chiba TFAU, Ooka YFAU, Kanogawa NFAU, Saito TFAU, Motoyama TFAU, et al. Sorafenib treatment in Child-Pugh A and B patients with advanced hepatocellular carcinoma: safety, efficacy and prognostic factors. Invest New Drugs. 2015;33:729–39.CrossRefPubMed Ogasawara S, Chiba TFAU, Ooka YFAU, Kanogawa NFAU, Saito TFAU, Motoyama TFAU, et al. Sorafenib treatment in Child-Pugh A and B patients with advanced hepatocellular carcinoma: safety, efficacy and prognostic factors. Invest New Drugs. 2015;33:729–39.CrossRefPubMed
37.
go back to reference Vitale A, Boccagni P, Kertusha X, Zanus G, D’Amico F, Lodo E, et al. Sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation? Transplant Proc. 2012;44:1989–91.CrossRefPubMed Vitale A, Boccagni P, Kertusha X, Zanus G, D’Amico F, Lodo E, et al. Sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation? Transplant Proc. 2012;44:1989–91.CrossRefPubMed
39.
go back to reference Boudou-Rouquette P, Narjoz C, Golmard JL, Thomas-Schoemann A, Mir O, Taieb F, et al. Early sorafenib-induced toxicity is associated with drug exposure and UGTIA9 genetic polymorphism in patients with solid tumors: a preliminary study. PLoS One. 2012;7:e42875.CrossRefPubMedPubMedCentral Boudou-Rouquette P, Narjoz C, Golmard JL, Thomas-Schoemann A, Mir O, Taieb F, et al. Early sorafenib-induced toxicity is associated with drug exposure and UGTIA9 genetic polymorphism in patients with solid tumors: a preliminary study. PLoS One. 2012;7:e42875.CrossRefPubMedPubMedCentral
40.
go back to reference Erdem L, Giovannetti E, Leon LG, Honeywell R, Peters GJ. Polymorphisms to predict outcome to the tyrosine kinase inhibitors gefitinib, erlotinib, sorafenib and sunitinib. Curr Top Med Chem. 2012;12:1649–59.CrossRefPubMed Erdem L, Giovannetti E, Leon LG, Honeywell R, Peters GJ. Polymorphisms to predict outcome to the tyrosine kinase inhibitors gefitinib, erlotinib, sorafenib and sunitinib. Curr Top Med Chem. 2012;12:1649–59.CrossRefPubMed
41.
go back to reference Herraez E, Lozano E, Macias RI, Vaquero J, Bujanda L, Banales JM, et al. Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib. Hepatology. 2013;58:1065–73.CrossRefPubMed Herraez E, Lozano E, Macias RI, Vaquero J, Bujanda L, Banales JM, et al. Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib. Hepatology. 2013;58:1065–73.CrossRefPubMed
Metadata
Title
Identification of clinical biomarkers for patients with advanced hepatocellular carcinoma receiving sorafenib
Authors
A. Lamarca
O. Abdel-Rahman
I. Salu
M. G. McNamara
J. W. Valle
R. A. Hubner
Publication date
01-03-2017
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 3/2017
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-016-1537-6

Other articles of this Issue 3/2017

Clinical and Translational Oncology 3/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine